Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 956-958

  Zhao, Xilin ^a   Wang, Jian Ying ^a   Xu, Chen ^a   Dong, Yuzhi ^a   Zhou, Jianfeng ^a   Domagala, John ^b   Drlica, Karl ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 7 (1 PIPERAZINYL) 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; CELL KILLING; DRUG ACCUMULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS AUREUS;

EID: 0031967763     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.956     Document Type: Note

References (21)

1. Bauernfeind, A. 1993. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI960, and CI-990. J. Antimicrob. Chemother. 31:505-522.
2. Chen, C.-R., M. Malik, M. Snyder, and K. Drlica. 1996. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J. Mol. Biol. 258:627-637.
3. Cohen, M., S. Yoder, M. Huband, G. Roland, and C. Courtney. 1995. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob. Agents Chemother. 39:2123-2127.
4. Coll, R., D. Gargallo-Viola, E. Tudela, M. A. Xicota, S. Llovera, and J. Guinea. 1996. Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones. Antimicrob. Agents Chemother. 40:274-277.
5. Deitz, W. H., T. M. Cook, and W. A. Goss. 1966. Mechanism of action of nalidixic acid on Escherichia coli. III. Conditions required for lethality. J. Bacteriol. 91:768-773.
6. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
7. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
8. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
9. Fisher, L. M., M. Oram, and S. Sreedharan. 1993. DNA gyrase: mechanism and resistance to 4-quinolone antibacterial agents, p. 145-155. In T. Andoh (ed.), Molecular biology of DNA topoisomerases. CRC Press, Inc., Boca Raton, Fla.
10. Foster, P. 1997. Nonadaptive mutations occur on the F′ episome during adaptive mutation conditions in Escherichia coli. J. Bacteriol. 179:1550-1554.
11. Hooper, D., and J. Wolfson. 1993. Mechanisms of bacterial resistance to quinolones, p. 97-118. In D. Hooper and J. Wolfson (ed.), Quinolone antimicrobial agents. American Society for Microbiology, Washington, D.C.
12. Ito, T., M. Matsumoto, and T. Nishino. 1995. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. Antimicrob. Agents Chemother. 39:1522-1525.
13. Ito, T., M. Otsuki, and T. Nishino. 1992. In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob. Agents Chemother. 36:1708-1714.
14. Kitamura, A., K. Hoshino, Y. Kimura, I. Hayakawa, and K. Sato. 1995. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1467-1471.
15. Klopman, G., D. Fercu, J.-Y. Li, H. S. Rosenkranz, and M. R. Jacobs. 1996. Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Res. Microbiol. 147:86-96.
16. Lewin, C., B. Howard, and J. Smith. 1991. Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase. J. Med. Microbiol. 34:19-22.
17. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
18. Novick, R. P., and R. Brodsky. 1972. Studies on plasmid replication. I. Plasmid incompatibility and establishment in Staphylococcus aureus. J. Mol. Biol. 68:285-302.
19. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
20. Sanchez, J. P., R. D. Gogliotti, J. M. Domagala, S. J. Gracheck, M. D. Huband, J. A. Sesnie, M. A. Cohen, and M. A. Shapiro. 1995. The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J. Med. Chem. 38:4478-4487.
21. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.